ABSTRACT
Clinical imaging has been the cornerstone to guide patient management and therapy strategies for oncology patients. In the last decades, the use of fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) has been increased and PET/CT has been introduced as the major imaging technique in international guidelines for staging and re-staging of many cancer types as well as for assessment of therapy response in oncological imaging. In this review, the contribution of fluorodeoxyglucose PET/CT in renal and bladder tumors is discussed under current guidelines.
References
1Lara PN, Jonasch E. Kidney cancer: principles and practice. Berlin: Springer; 2012.
2Leibovich BC, Lohse CM, Crispen PL, et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol 2010;183:1309-1315.
3De Castro GJ, McKiernan JM. Epidemiology, clinical staging, and presentation of renal cell carcinoma. Urol Clin N Am 2008;35:581-592.
4Karivedu V, Jain AL, Eluvathingal TJ, Sidana A. Role of positron emission tomography imaging in metabolically active renal cell carcinoma. Curr Urol Rep 2019;20:56.
5Petrella BL, Lohi J, Brinckerhoff CE. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2α in von Hippel–Lindau renal cell carcinoma. Oncogene 2005;24:1043-1052.
6Wang HY, Ding HJ, Chen JH, et al. Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell. Cancer Imaging 2012;12:464-474.
7Aide N, Cappele O, Bottet P, et al. Efficiency of [18F] FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol Imaging 2003;30:1236-12,45.
8Wang H-Y, Ding H-J, Chen J-H, Chao C-H, Lu Y-Y, LinW-Y, et al. Meta-analysis of the diagnostic performance of [18F]FDG-PETand PET/CT in renal cell carcinoma. Cancer Imaging 2012;12:464-74.
9Bouchelouche K, Choyke PL. PET/Computed tomography in renal, bladder, and testicular cancer. PET Clin 2015;10:361-374.
10Nagase Y, Takata K, Moriyama N, Aso Y, Murakami T, Hirano H. Investigative urology: immunohistochemical localization of glucose transporters in human renal cell carcinoma. Journal of Urology 1995;153:798-801.
11Divgi CR, Uzzo RG, Gatsonis C et al. Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol 2013;31:187-194.
12Takahashi M, Kume H, Koyama K, et al. Preoperative evaluation of renal cell carcinoma by using 18F-FDG PET/CT. Clin Nucl Med 2015;40:936-940.
13Ferda J, Ferdova E, Hora M, et al. 18F-FDG-PET/CT in potentially advanced renal cell carcinoma: a role in treatment decisions and prognosis estimation. Anticancer Res 2013;33:2665-2772.
14Safaei A, Figlin R, Hoh CK, et al. The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cell cancer. Clin Nephrol 2002;57:56-62.
15Alongi P, Picchio M, Zattoni F, et al. Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT. Eur J Nucl Med Mol Imaging 2016;43:464-473.
16Ma H, Shen G, Liu B, Yang Y, Ren P, Kuang A. Diagnostic performance of 18F-FDG PET or PET/CT in restaging renal cell carcinoma: a systematic review and meta-analysis. Nucl Med Commun 2017;38:156-163.
17Caldarella C, Muoio B, Isgro MA, Porfiri E, Treglia G, Giovanella L. The role of fluorine-18-fluorodeoxyglucose positron emission tomography in evaluating the response to tyrosine-kinase inhibitors in patients with metastatic primary renal cell carcinoma. Radiol Oncol 2014;48:219-227.
18Ueno D, Yao M, Tateishi U, et al. Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course. BMC Cancer 2012;12:162.
19Farnebo J, Gryback P, Harmenberg U, et al. Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma. BMC Cancer 2014;14:408.
20Yoon HJ, Paeng JC, Kwak C, et al. Prognostic implication of extrarenal metabolic tumor burden in advanced renal cell carcinoma treated with targeted therapy after nephrectomy. Ann Nucl Med 2013;27:748-755.
21Tabei T, Nakaigawa N, Kaneta T, et al. Early assessment with (18) F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict shortterm outcome in clear cell renal carcinoma treated with nivolumab. BMC Cancer 2019;19:298.
22Nakanishi Y, Kitajima K, Yamada Y, et al. Diagnostic performance of 11C-choline PET/CT and FDG PET/CT for staging and restaging of renal cell cancer. Ann Nucl Med 2018;32:658-668.
23Wong PK, Lee ST, Murone C, et al. In vivo imaging of cellular proliferation in renal cell carcinoma using 18F-fluorothymidine PET. Asia Ocean J Nucl Med Biol. 2014;2:3-11.
24Rhee H, Blazak J, Tham CM, et al. Pilot study: use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour. EJNMMI Res 2016;6:76.
25Ahn T, Roberts MJ, Abduljabar A, et al. A Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC). Mol Imaging Biol 2019;21:799-807.
26Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009;374:239-249.
27National Comprehensive Cancer Network. NCCN Guidelines: Bladder Cancer. Fort Washington: National Comprehensive Cancer Network; 2017.
28Mertens LS, Bruin NM, Vegt E, et al. Catheter-assisted 18F-FDG-PET/CT imaging of primary bladder cancer: a prospective study. Nucl Med Commun 2012;33:1195-1201.
29Yildirim-Poyraz N, Ozdemir E, Uzun B, Turkolmez S. Dual phase 18Ffluorodeoxyglucose positron emission tomography/computed tomography with forced diuresis in diagnostic imaging evaluation of bladder cancer. Rev Esp Med Nucl Imagen Mol 2013;32:214-221.
30Harkirat S, Anand S, Jacob M. Forced diuresis and dual-phase Ffluorodeoxyglucose- PET/CT scan for restaging of urinary bladder cancers. Indian J Radiol Imaging 2010;20:13-19.
31Anjos DA, Etchebehere EC, Ramos CD, Santos AO, Albertotti C, Camargo EE. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer. J Nucl Med 2007;48:764-770.
32Lu YY, Chen JH, Liang JA, et al. Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and metaanalysis. Eur J Radiol 2012;81:2411-2416.
33Soubra A, Hayward A, Dahm P, et al. The diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography and computed tomography in staging bladder cancer: a single-institution study and a systematic review with meta-analysis. World J Urol 2016;34:1229-1237.
34Jeong IG. Hong S, You D, Hong JH, Ahn H, Kim CS. FDG PET-CT for lymph node staging of bladder cancer: a prospective study of patients with extended pelvic lymphadenectomy. Ann Surg Oncol 2015;22:3150-156.
35Jadvar H, Quan V, Henderson RW, Conti PS. [F-18]-Fluorodeoxyglucose PET and PET-CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma. Int J Clin Oncol 2008;13:42-47.
36van de Putte EEF, Vegt E, Mertens LS, et al. FDG-PET/CT for response evaluation of invasive bladder cancer following neoadjuvant chemotherapy. Int Urol Nephrol 2017;49:1585-1591.
37Kibel AS, Dehdashti F, Katz MD, et al. Prospective study of [18F] fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol 2009;27:4314-4320.
38Mertens LS, Mir MC, Scott AM, et al. 18F fluorodeoxyglucose-- positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer. Urology 2014;83:393-398.
39Brunocilla E, Ceci F, Schiavina R, et al. Diagnostic accuracy of (11)C-choline PET/CT in preoperative lymph node staging of bladder cancer: a systematic comparison with contrast-enhanced CT and histologic findings. Clin Nucl Med 2014;39:e308-312.
40Maurer T, Souvatzoglou M, Kübler H, et al. Diagnostic efficacy of [11C]choline positron emission tomography/computed tomography compared with conventional computed tomography in lymph node staging of patients with bladder cancer prior to radical cystectomy. Eur Urol 2012;61:1031-1038.
